Argenx wins second FDA approval for Vyvgart in autoimmune nerve disease

After a string of clinical failures, the Dutch biotech argenx landed a much-needed win on Friday when the FDA approved its autoimmune disease drug, Vyvgart …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Dozens Who Were Told They Failed the Pathology Board Exam Actually Passed

Dozens of pathologists who were told they failed their specialty’s board exam over the past 2 years have been alerted that they actually passed. On

October 9, 2024

Tracking the U.S. bird flu outbreak has been hard. It’s about to get harder

If one can point to anything good about the H5N1 bird flu outbreak in dairy cattle — to be honest, there’s nothing good about this

October 28, 2024

Cannabis Sales Growth Was Slow in September

New Cannabis Ventures offers readers this easy-to-read exclusive summary of BDSA’s monthly cannabis sales data for 15 states. Cannabis sales decreased 1.2% sequentially in September, hurt

October 5, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.